Participant flow

Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer · Source last updated 2014-01-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants received pazopanib 800 milligrams (mg) once daily.

   id

   FG000

   title

   Pazopanib 800 mg

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         12

      type

      Adverse Event

   2. reasons

      1. group Id

         FG000

         num Subjects

         8

      type

      Withdrawal by Subject

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Sponsor Terminated Study

   4. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Physician Decision

   5. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Other

   6. reasons

      1. group Id

         FG000

         num Subjects

         7

      type

      Death

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         80

      type

      STARTED

   2. achievements

      1. comment

         Participants completed treatment (until disease progression), but may not have completed the study.

         group Id

         FG000

         num Subjects

         49

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         31

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice